


Dermatitis Market Player Collaborations Help Drive Growth Rate At 8%

*The Business Research Company's
Dermatitis Global Market Report 2022 –
Market Size, Trends, And Global Forecast
2022-2026*

LONDON, GREATER LONDON, UK, April 21, 2022 /EINPresswire.com/ -- The global dermatitis market has witnessed a trend of increasing mergers and acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today's world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolio and improve market presence. Companies are also strategically making M&As with a view to reduce competition and increase the scalability of their business.



The global [dermatitis market size](#) is expected to grow from \$5.92 billion in 2021 to \$6.37 billion in 2022 at a compound annual growth rate (CAGR) of 7.6%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global dermatitis market share is expected to reach \$8.06 billion in 2026 at a CAGR of 6.1%.

Read more on the Global Dermatitis Market Report

<https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report>

Major players covered in the global dermatitis industry are LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer HealthCare, Encore Dermatology Inc., Meda Pharmaceuticals, Allergan Plc. (Republic of Ireland) and Bristol-Myers Squibb.

Growth in atopic dermatitis market is primarily driven by the increasing global prevalence of the disease. Prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in

adults. The rising cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for the medicines to cure this disease. For example, according to the allergy asthma network 2020, approximately 31.6 million people in the United States have some form of atopic dermatitis. The prevalence of atopic dermatitis globally in children have 15-20 percent and in adults have 1 to 3 percent.

TBRC's global dermatitis market report is segmented by drug class into corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators, interleukin inhibitors, by distribution channel into hospital, retail pharmacies, drug stores, online or mail pharmacies, by route of application into topical, oral, injectable, by application into cancer, blood disorders, chronic diseases, infectious diseases.

[Dermatitis Global Market Report 2022](#) – By Drug Class (Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors), By Distribution Channel (Hospital, Retail Pharmacies, Drug Stores, Online Or Mail Pharmacies), By Route Of Application (Topical, Oral, Injectable), By Application (Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a dermatitis market overview, forecast dermatitis market size and growth for the whole market, dermatitis market segments, geographies, dermatitis market trends, dermatitis market drivers, restraints, leading competitors' revenues, profiles, and dermatitis market shares.

Request for a Sample of the Global Dermatitis Market Report

<https://www.thebusinessresearchcompany.com/sample.aspx?id=2413&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Skin Cancer Drugs Global Market Report 2022 – By Type (Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma), By End Users (Hospitals, Cancer Research Centers, Clinics), By Drug Class (Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report>

Dermatology Drugs Global Market Report 2022 – By Type (Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report>

Antifungals Global Market Report 2022 – By Drug Type (Echinocandins, Azoles, Polyenes, Allylamines), By End users (Hospitals & Clinics, Dermatology clinics, Other Users), By Route of

Administration (Oral, Parenteral, Topical), By Therapeutic Indications (Aspergillosis, Dermatophytosis, Candidiasis, Others) – Market Size, Trends, And Global Forecast 2022-2026
<https://www.thebusinessresearchcompany.com/report/antifungals-global-market-report>

About [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/569400243>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.